INDUCE Trial
Cross-source consensus on INDUCE Trial from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Other
Other
Highlighted claims
- The INDUCE trial is a multicentre, randomised, open-label, parallel-group phase II trial conducted in Japan. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The trial tests whether paclitaxel plus bevacizumab induction before atezolizumab plus nab-paclitaxel improves outcomes in PD-L1-positive metastatic triple-negative breast cancer. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The trial is randomised 1:1 between induction therapy and standard therapy groups. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The study is open-label because treatment schedules visibly differ after the first two cycles. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- Recruitment is ongoing in Japan, with planned enrolment completion by June 2026. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)